

2026 MGFA Scientific Session Agenda

September 29, 2026

Welcome and Keynote Address	
8:00 AM	Welcome Remarks — <i>Jenny McCue, MGFA Vice President, Research & Clinical Development</i>
8:05 AM	Introduction of Keynote Speaker — <i>Kelly G. Gwathmey, MD</i>
8:10 AM	Keynote Address — <i>Sarah Hoffmann, MD, MSc</i>
8:45 AM	Q&A — <i>Moderator: Kelly G. Gwathmey, MD</i>
Session A	
Biomarkers, Basic Science, and Diagnostics	
8:54 AM	Introduction — <i>Richard J. Nowak, MD, MS</i>
8:55 AM	Average Volume-Assured Pressure Support (AVAPS) in Monitoring Respiratory Muscle Weakness in Myasthenia Gravis — <i>Elizabeth Madole and Alex Fay, MD, PhD</i>
9:03 AM	Revisiting the Neuromuscular Junction in Acetylcholine Receptor Antibody-Positive Myasthenia Gravis: A Multimodal Study of Human Endplate Pathology — <i>Sarah Hoffmann, MD, MSc</i>
9:10 AM	iPSC-derived Neuromuscular Junction Organoids Recapitulate Presynaptic Dysfunction in Lambert-Eaton Myasthenic Syndrome — <i>Caleb Aguayo, PhD Candidate</i>
9:17 AM	Complement C5 Inhibition Preserves the Neuromuscular Junction in Myasthenia Gravis: An Integrated Morphology and In Vivo Nerve-evoked Muscle Function Biomarker Platform in Rodent Models — <i>Chris Ward, PhD</i>
9:24 AM	Q&A — <i>Moderator: Richard J. Nowak, MD, MS</i>
9:30 AM	Coffee Break
Session B	
Therapeutics and Clinical Trials	
10:00 AM	Introduction — <i>Tuan Vu, MD and Neelam Goyal, MD</i>
10:01 AM	Psychometric Evaluation of the Myasthenia Gravis Impairment Index Patient Reported Outcome Ocular Score in Ocular Myasthenia Gravis: Results From a Phase 3 Clinical Trial in Ocular Myasthenia Gravis — <i>Jeff Guptill, MD, MHS, MA</i>
10:08 AM	Efficacy and Safety of Efgartigimod in Participants With Generalized Myasthenia Gravis Who Lack Detectable Anti-Acetylcholine Receptor Antibodies: One-Year Results of ADAPT SERON — <i>James F. Howard, Jr., MD, FAAN</i>
10:15 AM	Primary Analysis of Phase 2 of KYSA-6, an Open-Label, Single-Arm, Multicenter Study of Miv-cel (KYV-101), a Fully Human CD19 Chimeric Antigen Receptor T-Cell Therapy in Generalized Myasthenia Gravis — <i>Srikanth Muppidi, MD</i>
10:22 AM	Comparison of Cemdisiran vs Placebo on Hospitalization Rate in the Phase 3 Double-Blind NIMBLE Trial — <i>Ali Habib, MD</i>
10:29 AM	Telitacicept for Generalized Myasthenia Gravis: Depth of Response Across 48 Weeks in a Phase 3 Study Conducted in China — <i>Richard J. Nowak, MD, MS</i>
10:36 AM	Slow Channel Congenital Myasthenic Syndrome: Treatment Outcomes and Cohort Insights — <i>Eduardo Estephan, MD, PhD</i>
10:43 AM	Durability of Response Following Retreatment with Descartes-08, an Autologous BCMA-directed mRNA CAR-T Cell Therapy, in Generalized Myasthenia Gravis: 12-Month Follow-up — <i>James F. Howard, Jr., MD, FAAN</i>
10:50 AM	RESET-MG: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Generalized Myasthenia Gravis — <i>Ali Habib, MD</i>

Therapeutics and Clinical Trials (continued)

10:57 AM	Clinical Deterioration, Rescue Therapy, and Hospitalization Among Patients with Generalized Myasthenia Gravis (gMG): Results From the PREVAIL Trial of Gefurulumab — <i>James Winkley, MD</i>
11:04 AM	FCGR3A Polymorphisms and Treatment Timing in Rituximab Response in MuSK-MG — <i>Jonathan Morena, DO</i>
11:11 AM	Q&A — <i>Moderators: Tuan Vu, MD and Neelam Goyal, MD</i>
11:30 AM	Lunch (Not Served at MGFA Scientific Session)

Session C

Seronegative MG and Congenital Myasthenic Syndromes

1:00 PM	Introduction — <i>Gianvito Masi, MD</i>
1:01 PM	Adeno-associated Virus-mediated Gene Therapy of Synaptotagmin 2-Deficient Mice — <i>Olivia Morgans, DVM Candidate</i>
1:08 PM	Determining Autoimmunity in Seronegative Myasthenic Syndromes: Insights From Live-CBA Testing and a Human Muscle Cell Assay in a Large Central European Cohort — <i>Sarah Hoffmann, MD, MSc</i>
1:15 PM	Q&A — <i>Moderator: Gianvito Masi, MD</i>

Patient Care, Outcomes, Digital Health & Real-World Evidence

1:20 PM	Introduction — <i>Ali Habib, MD</i>
1:21 PM	Interpreting Clinically Meaningful Improvement on the Myasthenia Gravis Impairment Index (MGII) Patient Reported Outcome (PRO) Ocular Score: Responder Analyses From a Phase 3 Clinical Trial in Ocular MG — <i>Jeff Guptill, MD, MHS, MA</i>
1:28 PM	Validation of Myasthenia Gravis Outcome Measure Thresholds in a Real-World Clinical Practice Cohort: A Retrospective Duke MG Registry Study — <i>Karandeep Singh Bhatti, MBBS</i>
1:35 PM	Integrated Group-based and Machine Learning Analysis Reveals Sex-related Clinical Signatures in Autoimmune Myasthenia Gravis — <i>Paolo Doksani, MD</i>
1:42 PM	ME&MG™ Digital Biomarkers Scores Reflect MGFA Severity Classification — <i>Bhaskar Dutta, PhD</i>
1:49 PM	Placebo-arm Response in Generalized Myasthenia Gravis Clinical Trials: A Systematic Review and Meta-analysis — <i>Hazem Iaali, MD</i>
1:56 PM	Q&A — <i>Moderator: Ali Habib, MD</i>

Closing Remarks

2:15 PM Closing Remarks & Wrap-Up — *Jenny McCue, Vice President, Research & Clinical Development, MGFA*

MGFA Scientific Session Poster Session

2:30 PM Converse with researchers about their published work.
- 3:30 PM *Floridian Ballroom D-I (Lobby Level)*

Find poster numbers and read full abstracts:

myasthenia.org/SS2026

